Abstract
Objective: The aim was to report a new family with congenital FX deficiency.
Patients and Methods: The proposita is a 41 year old female with a moderate bleeding tendency (easy bruising, menorrhagia). Parents were not consanguineous. Family history was positive for a mild bleeding tendency.
Results: Coagulation and genetics studies revealed that the proposita and two of her siblings were heterozygotes for a new mutation Cys241Gly in exon 6 but had different FX level (2-3% of normal in the proposita and about 50% in the two siblings. The same was true for one of her three children. The mother and the other two children of the proposita had also slightly decreased FX levels but no mutation. On the suspicion that the proposita was carrying another defect which had escaped the Sanger method, we carried out a whole exome analysis and discovered that the proposita and one of her siblings were also homozygous for a mutation of a known polymorphism (c.503-57C>T).
The daughter of the proposita was instead, besides being a carrier of the missense new mutation Cys241Gly, heterozygous for the same polymorphism. The mother and two other daughters were also heterozygous for the polymorphism. There were no deletions or duplications.
Conclusion: The polymorphism present in the family seems to be capable of potentiating the defect induced by the new mutation. This, safe for epigenetics phenomena, is the only possible explanation for the discrepancy found in the FX level between mother and daughter despite the fact that both carried the same new mutation.
Keywords: FX deficiency, polymorphism, potentiating effect, new mutation, menorrhagia, plasma.
Graphical Abstract
Cardiovascular & Hematological Disorders-Drug Targets
Title:Congenital FX Deficiency Rio Tercero: A New Heterozygous Missense Mutation (Cys241Gly) with a Potentiating Effect by a Polymorphism (c. 503-57C>T)#
Volume: 17 Issue: 2
Author(s): Antonio Girolami*, Salvador Minoldo, Silvia Ferrari, Diego Colussi, Anna Maria Lombardi and Hugo Guglielmone
Affiliation:
- Department of Medicine, University of Padua Medical School, Padua,Italy
Keywords: FX deficiency, polymorphism, potentiating effect, new mutation, menorrhagia, plasma.
Abstract: Objective: The aim was to report a new family with congenital FX deficiency.
Patients and Methods: The proposita is a 41 year old female with a moderate bleeding tendency (easy bruising, menorrhagia). Parents were not consanguineous. Family history was positive for a mild bleeding tendency.
Results: Coagulation and genetics studies revealed that the proposita and two of her siblings were heterozygotes for a new mutation Cys241Gly in exon 6 but had different FX level (2-3% of normal in the proposita and about 50% in the two siblings. The same was true for one of her three children. The mother and the other two children of the proposita had also slightly decreased FX levels but no mutation. On the suspicion that the proposita was carrying another defect which had escaped the Sanger method, we carried out a whole exome analysis and discovered that the proposita and one of her siblings were also homozygous for a mutation of a known polymorphism (c.503-57C>T).
The daughter of the proposita was instead, besides being a carrier of the missense new mutation Cys241Gly, heterozygous for the same polymorphism. The mother and two other daughters were also heterozygous for the polymorphism. There were no deletions or duplications.
Conclusion: The polymorphism present in the family seems to be capable of potentiating the defect induced by the new mutation. This, safe for epigenetics phenomena, is the only possible explanation for the discrepancy found in the FX level between mother and daughter despite the fact that both carried the same new mutation.
Export Options
About this article
Cite this article as:
Girolami Antonio*, Minoldo Salvador , Ferrari Silvia , Colussi Diego , Lombardi Maria Anna and Guglielmone Hugo , Congenital FX Deficiency Rio Tercero: A New Heterozygous Missense Mutation (Cys241Gly) with a Potentiating Effect by a Polymorphism (c. 503-57C>T)#, Cardiovascular & Hematological Disorders-Drug Targets 2017; 17 (2) . https://dx.doi.org/10.2174/1871529X17666170908105839
DOI https://dx.doi.org/10.2174/1871529X17666170908105839 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Recombinant Factor VIIA, its Clinical Properties, and the Tissue Factor Pathway of Coagulation
Mini-Reviews in Medicinal Chemistry Methods for Evaluating Sensory, Affective and Cognitive Disorders in Neuropathic Rodents
Current Neuropharmacology Sympathetic and Baroreflex Function in Hypertension: Implications for Current and New Drugs
Current Pharmaceutical Design ATP-Sensitive Potassium Channel Openers and 2,3-Dimethyl-2-Butylamine Derivatives
Current Medicinal Chemistry Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer’s Disease: Results from a Double-Blind, Placebo-Controlled Trial
Current Alzheimer Research Platelets in Thrombosis and Hemostasis: Old Topic with New Mechanisms
Cardiovascular & Hematological Disorders-Drug Targets Caveolin-1 and ATP Binding Cassette Transporter A1 and G1-Mediated Cholesterol Efflux
Cardiovascular & Hematological Disorders-Drug Targets Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism Macrophage Infiltration, Lectin-Like Oxidized-LDL Receptor-1, and Monocyte Chemoattractant Protein-1 are reduced by Chronic HMG-CoA Reductase Inhibition
Current Neurovascular Research Involvement of P-glycoprotein and Multidrug Resistance Associated Protein 1 in the Transport of Tanshinone IIB, a Primary Active Diterpenoid Quinone from the Roots of Salvia miltiorrhiza, Across the Blood-Brain Barrier
Drug Metabolism Letters New Emerging Prospects in the Pharmacotherapy of Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Exercise-Induced Cardioprotection via eNOS: A Putative Role of Red Blood Cell Signaling
Current Medicinal Chemistry Nanotechnology Advances in Brain Tumors: The State of the Art
Recent Patents on Anti-Cancer Drug Discovery